Fulltext

UFO registry: final analysis of baseline data from patients with advanced prostate cancer in Asia

Ye D 1 , Kanesvaran R 2 , Chiong E 3 , Lojanapiwat B 4 , Pu YS 5 , Rawal SK 6 Show all authors , Aik OT 7 , Zeng H 8 , Chung BH 9 , Ashani MYN 10 , Ohyama C 11 , Kim CS 12 , Hu Z 13 , Tsai YS 14 , Razack AHA 7 , Singh A 15 , Liu Y 16 , Uemura H 17

Affiliations 

  • 1 Fudan University Shanghai Cancer Center, Shanghai, China
  • 2 Division of Medical Oncology, National Cancer Centre, Singapore
  • 3 Department of Urology, National University Hospital, National University Health System, Singapore
  • 4 Division of Urology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
  • 5 Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
  • 6 Rajeev Gandhi Cancer Institute, New Delhi, India
  • 7 Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 8 Department of Urology, West China Hospital, Sichuan University, Chengdu, China
  • 9 Department of Urology and Urological Science Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
  • 10 Urology Department, Institute Urology and Nephrology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
  • 11 Department of Urology, Hirosaki University Graduate School of Medicine, Aomori, Japan
  • 12 Urology Institute, Ewha Womans University Mokdong Hospital, Seoul, South Korea
  • 13 Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China
  • 14 Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
  • 15 Regional Medical Affairs, Janssen, Singapore
  • 16 Department of Global Real-World Evidence, Janssen Pharmaceuticals LLC, Raritan, NJ, USA
  • 17 Department of Urology, Kindai University Faculty of Medicine, Osaka-Sayama 589-8511, Japan
Ther Adv Med Oncol, 2024;16:17588359241293393.
PMID: 39583953 DOI: 10.1177/17588359241293393

Abstract

BACKGROUND: The incidence of prostate cancer (PC) is increasing in Asian countries. The epidemiology of PC, its treatment including the use of novel therapeutic options, impacts on quality of life, and clinical outcomes of patients with PC in Asia, are not well documented.

OBJECTIVES: To describe the demographic and disease features of the full cohort of patients enrolled in the United in Fight against prOstate cancer (UFO) registry.

DESIGN: The UFO registry was a multi-national, longitudinal, observational study of patients with PC presenting to participating tertiary care hospitals in eight Asian countries/regions.

METHODS: Patients with high-risk localized PC (HRL), non-metastatic biochemically recurrent, or metastatic PC were consecutively enrolled from September 14, 2015 until September 1, 2020 and followed for up to 5 years.

RESULTS: Among the full cohort of 3635 patients, 425 had HRL, 389 had non-metastatic biochemically recurrent, and 2821 had metastatic PC. Median follow-up time was 4.2, 4.2, and 2.6 years, respectively. At first diagnosis, the mean age ranged from 65.7 to 69.1 years, 38.5% had extra-capsular tumor extension, 34.0% had regional lymph node metastases, and 65.1% had distant metastases. Quality-of-life scores at enrollment were significantly worse in patients with metastatic disease. Decisions to start therapy were mainly driven by treatment guidelines and disease progression. The decision to discontinue hormonal therapy was often due to disease progression. Few patients received novel hormonal therapies despite their availability.

CONCLUSION: The UFO registry provides a detailed, contemporary picture of the characteristics, treatment, and outcomes of patients with PC in Asia. There is an unmet medical need to improve access to novel agents in Asia, aiming to improve quality of life and clinical outcomes.

TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT02546908, Registry Identifier: NOPRODPCR4001.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications